TRACON Pharmaceuticals, Inc.
TCON · OTC
6/30/2024 | 3/31/2024 | 12/31/2023 | 9/30/2023 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.05 | -0.00 |
| FCF Yield | -82.93% | -12.97% | -6.05% | 227.84% |
| EV / EBITDA | 1.01 | -3.65 | 1.94 | -0.04 |
| Quality | ||||
| ROIC | 116.90% | 293.33% | 255.97% | 69.43% |
| Gross Margin | 100.00% | 96.00% | 99.90% | 0.00% |
| Cash Conversion Ratio | 0.98 | 0.80 | -1.19 | 1.40 |
| Growth | ||||
| Revenue 3-Year CAGR | – | 2,298,507.07% | 2,292,180.88% | 196.29% |
| Free Cash Flow Growth | -8.89% | -387.16% | -103.47% | 357.26% |
| Safety | ||||
| Net Debt / EBITDA | 2.16 | 2.46 | -19.10 | -0.62 |
| Interest Coverage | 0.00 | -60.60 | 0.00 | -2.46 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | 0.00 | -60,322.50 | -76,320.00 | -238,995.00 |